Project Grant HT94252410893

This Project Grant award of $543,221.00 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) is supporting research at the Albert Einstein College of Medicine to better understand the cellular and molecular mechanisms driving lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: 1) Define the critical de-differentiated cell states involved in BLBC progression and explore strategies to target these cells for cancer...

The federal Project Grant award of $1,597,224.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program to support the research project "BCL-XL IN BREAST CANCER METASTASIS AND THERAPY" at Baylor College of Medicine in Houston, Texas. The award, with a performance period from August 1, 2024 to July 31, 2027, will fund advanced biomedical research initiatives focused on transforming healthcare for military service...

The federal Project Grant award R01CA289387, totaling $657,121.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports research conducted by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida to develop a novel dendritic cell therapy for treating leptomeningeal disease (LMD), a severe complication that occurs in 5% of advanced-stage breast cancer patients. The research aims to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $642,429 to The University of Texas Southwestern Medical Center (UT Southwestern) to study acquired cross-resistance in small cell lung cancer (SCLC). The research aims to understand how molecular alterations, particularly extrachromosomal amplification of MYC, MYCN, and MYCL genes, drive resistance to multiple cancer therapies in SCLC tumors. The project utilizes a panel of 72...

This $895,779 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to advance the science of brain metastases from HER2-positive breast cancer. The key products and services to be delivered under this 7-year grant include: Understanding the fundamental biology and genetic risk factors of HER2-positive breast cancer metastases to the brain through patient tissue-based research. Developing real-time visualization techniques to track cancer cells and...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $700,690 to Health Research, Inc. at Roswell Park Comprehensive Cancer Center to decipher the molecular mechanisms underlying breast cancer bone metastasis. The overarching goals are to understand how the transcriptional coactivators YAP/TAZ drive the progression of microscopic to established bone metastases, and to identify new therapeutic targets to treat both early and advanced...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,983 to Northwestern University to conduct research on the role of the protein PlexinB2 in the formation and behavior of circulating tumor cell (CTC) clusters in triple-negative breast cancer (TNBC). The research aims to elucidate the clinical relevance of the PlexinB2 pathway, the molecular mechanisms by which it drives CTC cluster formation, and the potential of targeting PlexinB2...

This Project Grant award of $683,150 from the Defense Health Agency supports research by The University of Texas Health Science Center at San Antonio (UTHSCSA) to develop combined therapies using hemichannel-targeting antibodies and FDA-approved therapies to treat breast cancer bone metastasis. The research is funded under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for service...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $564,695 to The University of Texas MD Anderson Cancer Center to study a new driver and therapeutic vulnerability of bone metastasis in breast cancer. The research aims to explore the role of the protein acyl-CoA binding protein (ACBP) in promoting bone metastasis through regulating lipid metabolism and protecting cancer cells from ferroptosis. The 5-year project, starting on June 10,...

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $527,159 in funding to Brigham & Women's Hospital, a subsidiary of Partners Healthcare System, to conduct research on the role of DNA damage and cell fate plasticity in the initiation of BRCA1-related basal-like breast cancer. The key objectives of the research are to: 1) study whether BRCA1-deficient luminal mammary cells acquire a fetal mammary stem cell-like gene expression program...